CONTACT US Unlocking the Therapeutic Potential of Complex GPCRs Our People Our Science Orion Biotechnology is a clinical stage company discovering and developing next-generation G Protein-Coupled Receptor (GPCR)-targeted therapeutics for the treatment of cancer and other serious diseases. Orion’s novel drug modality involves precision engineering ligands of peptide and protein GPCRs to develop analogs with ... Read moreHome
Location: Canada, Ontario, Ottawa
Employees: 11-50
Founded date: 2011
Investors 1
| Date | Name | Website |
| - | Cantilever... | cantilever... |
Mentions in press and media 4
| Date | Title | Description | Source |
| 06.03.2024 | Orion Biotechnology Presenting at the 3rd GPCR-Targeted Drug... | - | globenewsw... |
| 16.12.2021 | Evofem Biosciences and Orion Biotechnology Launch Collaborat... | SAN DIEGO, Dec. 16, 2021 /PRNewswire/ -- Evofem Biosciences, Inc. (NASDAQ: EVFM) and Orion Biotechno... | marketscre... |
| 23.11.2021 | Keiretsu Forum Held Largest Investor Gathering to Showcase 2... | Over 1,700 registered investors, more than 1,900 expressions of interest, 6 Most Valued Company winn... | marketscre... |
| 17.06.2021 | ORION BIOTECHNOLOGY SECURES $11.5M SERIES A FINANCING | ottawa, canada, June 17, 2021 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a clinical-stage ... | marketscre... |